Mapping the Knowledge Landscape of Antidiabetic Agent Research: A Scientometric Analysis of Trends, Collaboration, and Emerging Themes (2020–2026)

Abstract

This study estimates the advancement of antidiabetic-agent research in the Journal of Medicinal Chemistry (JMC) during 2020–2026 concluded a scientometric valuation of 87 Scopus-indexed records. The collection comprises 72 research articles, 14 review papers and 0 errata, with a increasing citation count of 2,611. The publications received an average of 30.01 citations each, with a median of 13 citations and a calculated h-index of 26. Publication productivity reached its highest level in 2021, with 18 records, while 7 records were present in the 2026 snapshot. A strong collaborative pattern is manifest: 87 of the 87 records with recognizable author strings are multi-authored, giving a K. Subramanyam degree of collaboration of 1.00. The dataset contains 851 separate author-name strings and 978 Scopus author identifiers. Country analysis based on affiliation strings shows Italy, the United States, China, India, Germany and France among the most frequently represented national affiliations. Scopus Index Keywords emphasize antidiabetic agents, diabetes mellitus, insulin, protein-tyrosine phosphatase 1B, glucose transport, glucagon-like peptide-1, α-glucosidase, metabolic signaling and related therapeutic thoughts. The literature progressively combines small-molecule enzyme and transporter inhibition with peptide engineering, metabolic inflammation incretin pharmacology, β-cell biology and translational drug discovery. Highly cited records include studies of oral GLP-1 receptor agonism, insulin, cagrilintide, DYRK1A, PTP1B inhibitors, NLRP3 and metabolic signaling. Overall, the results show a multidisciplinary and strongly collaborative JMC landscape in which predictable glucose-lowering approaches coexist with receptor-selective, pathway-directed and peptide-based approaches.